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Abstract – The application of a “catch and release” approach to palladium catalysed multi-component cascade reactions leads to diverse 
libraries of pharmacologically interesting small molecules in high yield and with excellent purity. 
 © 2007 Elsevier Science. All rights reserved 
1. Introduction 
The development of high-throughput screening emphasised 
the need for new techniques to synthesise compound 
libraries with ‘drug-like’ properties. Classical multi-step 
solution-phase synthesis cannot generate large numbers of 
compounds in a parallel fashion, and thus new methods 
have been developed to enable rapid synthesis and 
separation of a desired compound from by-products and/or 
excess reagents. One way to approach this problem is to 
attach the desired compound to a solid support, and to 
separate it from by-products / reagents by filtration. The 
desired compound is then released from the resin and 
isolated in high purity.1-3
This resin-bound approach has become central to the drug 
discovery process in the pharmaceutical industry. Reactions 
can be driven to completion through the use of excess 
reagents; resin-washing is a very simple way of removing 
undesired reagents and by-products; physical losses are 
minimised since the product remains attached to the resin 
throughout the synthetic process; and the process is highly 
amenable to automation. Nevertheless, there are limitations 
to undertaking synthetic processes with resin-bound 
products, in particular the diminished rate of some 
reactions compared to their solution-phase equivalent, and 
the often laborious development time for optimising 
solution-phase chemistry on a solid support.4,5  
Recent developments in combinatorial synthesis have 
focused on these limitations. One method, known as ‘resin 
capture’ or ‘catch and release’, minimises these drawbacks 
by initiating the synthesis of a library in solution and 
subsequently transferring the product of the solution-phase 
synthesis onto solid support for further manipulation and 
isolation. First published by Armstrong et al to synthesise 
tetrasubstituted ethylenes,6 the ‘catch and release’ approach 
enables the facile synthesis of quite complex products with 
exceptional purity and is now a commonly used 
combinatorial technique.7-16
2. Palladium-catalysed “catch and release” cascade 
The objective of the present study was to apply an extended  
“catch and release” strategy to the palladium-catalysed 
three-component cascade reaction incorporating aryl 
iodides, allenes and nitrogen nucleophiles (Scheme 1). 
Previous work within our group had shown that the 3-
component catalytic cascade was amenable to solid-phase 
synthesis when the aryl iodide17 or allene18 was pre-
attached to the resin. Our envisaged approach would extend 
this methodology in two ways: by utilising a resin-bound 
nucleophile to capture the product onto resin; and by 
carrying out further manipulation of the resin-bound 
product prior to cleavage. It was hoped that this method 
would allow the rapid construction of diverse libraries of 
pharmacologically interesting small molecules.  
Thus the π-allylpalladium species 1 (formed in solution 
from an allene and aryl iodide) would be captured by a 
resin-bound amino group to give resin-bound product 2. 
Further manipulation of 2 by, for example, acylation with 
an acid chloride would provide resin-bound allylic amide 3. 
This could be further functionalised or cleaved immediately 
to give 4.  
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2.1 Development of Methodology 
A good resin for ‘catch and release’ strategies is Rink 
Amide MBHA resin 5. Deprotection of the Fmoc group 
leaves a primary amino group which is an ideal nucleophile 
for our cascade and the presence of the methoxy 
substituents facilitates cleavage via extended delocalisation 
of the carbocation via the oxygen lone pairs.  
 
Having selected an appropriate resin, we decided to test the 
viability of the cascade using allene gas and a simple aryl 
iodide (Scheme 2).  
The resin was deprotected using 20% piperidine in 
dimethylformamide and, after washing the resin, the 3-
component catalytic cascade was carried out using very 
similar reaction conditions to those employed in solution-
phase.  Thus 1.1 equivalents of the aryl iodide, 2.0 
equivalents of potassium carbonate, 2.5 mol % of tris 
(dibenzylideneacetone) dipalladium (0) and 10 mol % of 
tri-2-furyl phosphine were reacted at 80 °C over 22 h. After 
washing, the resin-bound product 6 was acylated with 
excess benzoyl chloride (2 equivalents) using triethylamine 
as base (3 equivalents) in dichloromethane to give 7 which 
after further washing was cleaved to give allylic amide 8. 
The reaction was then repeated using different aryl iodides 
to provide a small library of allylic amides (Table 1). 
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Scheme 1
The third column of Table 1 shows that the reaction yields 
varied from a low of 55% to a high of 95%. These yields 
represent the isolated yields of the final product after all 
four synthetic steps (deprotection, the 3-component 
cascade, acylation and cleavage from the resin) and after 
any subsequent purification. Even the lowest overall yield 
of 55% represents an average yield exceeding 85% for each 
individual step. In the circumstances the yields were 
excellent, and it was pleasing to note that although we were 
using a primary amine as nucleophile in the cascade, no 
bis-adduct was formed as a by-product. 
N
H O
O
NH.Fmoc
OMe OMe
5
We were particularly encouraged by the purity exhibited by 
the products (the final column in Table 1). Purity was 
assessed by carrying out an HPLC analysis of the crude 
product directly after TFA cleavage (the only proviso being 
that some of the products were washed with ether before 
being left under high vacuum overnight to remove residual 
traces of TFA). For all the entries in Table 1, the purity of 
the compound is at least 95%. Indeed, for the methyl ester 
15 the crude product was analytically pure by HPLC with 
no discernible trace of impurity. All HPLC analyses were 
recorded at 254 nm using a Luna 5μ (250 x 4.6 mm) 
phenyl-hexyl column.   
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r.t., 1 h
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Pd2dba3, TFP
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r.t., 20 min
Scheme 2
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Table 1: Cascade products using conditions shown in Scheme 2 
Entry Product 
Yield 
(%)a
Purity 
(%)b
1 N
H
NO2
O
8  
95 97 
2 N
H
O
9  
64 96 
3 N
H
O
Cl
Cl
10  
55 96 
4 N
H
O
N Cl
11  
68 99 
5 N
H
O
CF3
12  
75 98 
6 
N
H
O
CF3
CF3
13  
55 97 
7 N
H
O
CO2Et
14
 
76 98 
8 N
H
O
CO2Me
15
 
82 >99 
a) Isolated yield after column chromatography and/or crystallisation. b) 
HPLC analysis of crude product directly after cleavage. 
Figure 1 shows the 1H NMR spectrum of 13 recorded 
directly after cleavage and is typical of the spectra of crude 
products obtained from this solid phase synthetic route.   
 
It is noticeable from Table 1 that all of the products are 
derived from aryl iodides which are rendered electron 
deficient by either the presence of an electron withdrawing 
substituent (entries 1, 3 to 8) or by extended conjugation 
(entry 2).  
Figure 1. 1H NMR (CDCl3) of compound 13 directly after resin-cleavage 
 
Numerous attempts to incorporate the aryl / vinyl iodides 
shown in Figure 2 into the standard protocol proved 
unsuccessful. A complex mixture of products was obtained 
on cleavage from the resin, comprising at best 20-30% 
desired product and often significantly less. Using an 
excess of aryl iodide (up to 5 equivalents), extending the 
reaction time up to 48 h, altering the solvent (acetonitrile 
and toluene) and varying the reaction temperature all failed 
to improve product yield and purity. 
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           Figure 2 
 
Electron withdrawing groups activate the carbon-iodine 
bond to oxidative addition by the nominally electron-rich 
palladium(0). However, this cannot alone explain the 
reaction failure as aryl iodides of the type shown in Figure 
2 undergo the 3-component cascade reaction using standard 
nitrogen nucleophiles in solution.19
 
Rather, a combination of both the nature of the nitrogen 
nucleophile and the nature of the π-allylpalladium 
intermediate is likely to be decisive here. The resin-bound 
amino group is sterically hindered, the polymer backbone 
hinders access of the amino group to the π-allylpalladium 
species, whilst the close proximity of the sp2 carbons of the 
surrounding aryl groups inductively reduces the calculated 
pKa, both of which impact adversely on the nucleophilicity 
of the amine. Therefore, in order for the cascade process to 
proceed satisfactorily, the π-allylpalladium species (which 
acts as the electrophile) is likely to require enhanced 
reactivity. The presence of an electron withdrawing group, 
which will render that species even more electrophilic, 
must tip the balance in favour of nucleophilic attack to give 
the desired cascade product. Thus a combination of steric 
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and electronic factors prevents the cascade from proceeding 
unless an activated aryl iodide is employed. 
 
2.2 Exploring Diversity in the Cascade  
The compounds in Table 1 are derived using benzoyl 
chloride as the acylating agent. However, it is possible to 
use other reagents in order to introduce further diversity 
into the final products (Table 2). 
Thus other acid chlorides are tolerated (entry 1) as are aryl 
and alkyl isocyanates (entries 2 and 3) and sulfonyl 
isocyanates (entry 4). As before, the products are obtained 
in high yields and excellent purity. 
Attempts to extend the scope of the cascade using 
isothiocyanates and sulfonyl chlorides as reagents have, 
thus far, proved less successful (entries 5 and 6). Since both 
20 and 21 fell below our purity cut-off they were not 
processed any further. 
An explanation for the poor reactivity of isothiocyanates 
and sulfonyl chlorides again relates to the nucleophilicity of 
the resin-bound amino group. Following the 3-component 
catalytic cascade, the resulting secondary amine will have 
both increased steric hindrance and an even lower pKa 
(owing to the inductive effect of the sp2 carbon of the exo-
methylene double bond). Therefore the nucleophilicity of 
that amino group will be relatively low, explaining why the 
product can attack the reactive acyl chloride and isocyanate 
reagents, but not the relatively less reactive isothiocyanate 
and sulfonyl chloride species. The order of reactivity 
suggested by these experiments is acyl chloride > 
isocyanate > isothiocyanate > sulfonyl chloride. 
We have however managed to incorporate substituted 
allenes into the cascade (Scheme 3). 
Thus cyclohexyl allene 22 undergoes the cascade reaction 
under standard conditions to form resin-bound product 23.  
 Table 2: Cascade products from alternative acylating agents  
a) Isolated yield after column chromatography and/or crystallisation. b) 
HPLC analysis of crude product directly after cleavage. ND = not done 
(Conditions as per Table 1). 
 
Acylation with benzoyl chloride proceeded smoothly to 
Entry Product 
Yield 
(%)a
Purity 
(%)b
1 NH
O
CO2Me
16
 
71 94 
2 N
H
N
H
O 17  
90 92 
3 N
H
N
H
O
NO2
18  
64 90 
4 S
O O
N
H
N
H
O
NO2
19  
68 >99 
5 N
H
N
H
S 20  
ND 77 
6 N
H
S
O O
O2N
21  
ND <20 
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20% piperidine / DMF
r.t., 1 h
+ . +
Pd2dba3, TFP
K2CO3, DMF
80oC, 22 h
+
TEA, DCM
0oC to r.t., 16 h
23 24
20% TFA / DCM
r.t., 20 min
22
25,  66% yield,  97% purity
11:1 Z:E mixture  
Scheme 3
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give 24 which after cleavage gave compound 25 in 66% 
yield and very high purity (97%). 
The product was obtained as an 11:1 mixture of Z:E 
geometric isomers (as measured by HPLC). N.O.e studies 
showed the Z-isomer to be the major product (Figure 3). 
 
              Figure 3 
The high selectivity for the Z-isomer arises from the 
preferential capture of the anti-π-allylpalladium species by 
the resin-bound nucleophile (Scheme 4). 
The π-allyl palladium intermediate can interconvert 
between the sterically congested syn-π-allyl 27, where the 
cyclohexyl is in very close proximity with the aryl group, 
and anti-π-allyl 26, where steric congestion is much 
reduced via η1-allyl palladium (II) species. Our extensive 
work in this general area suggests the anti-π-allyl 26 is 
formed initially and that anti-syn isomerisation reflects the 
rate of nucleophilic attack. Thus steric impediments to 
nucleophilic attack permit the isomerisation and lead to Z/E 
mixtures.  
Thus, in the case in hand, steric bulk provided by the Rink 
amide linker surrounding the amino group is responsible. 
Diversity can thus be incorporated into the cascade via the 
aryl iodide, allene and acylating agent. However, in order 
to maximize the potential synthetic applicability it was 
important to develop a strategy which would allow the 
synthesis of acids via the cascade approach, thereby 
allowing further resin-bound coupling reactions.  
Standard methods for hydrolysis of the resin-bound aryl 
esters proved unsatisfactory. Although heating to 65 0C 
with NaOH in 1:1 EtOH/water did lead to complete 
hydrolysis of resin-bound ethyl ester 14, it proved difficult 
to reliably repeat these results; full conversion was not 
always achieved and there appeared to be a difficult 
compromise between solvents which suited the hydroxide 
base and solvents which allowed the resin to swell 
sufficiently to undergo hydrolysis. 
N
H
O
NO2
H
H
H
H H
7.3%
8.3%
An alternative literature strategy was to use the t-butyl ester 
and to hydrolyse with zinc bromide in DCM.20 Thus 4-
iodobenzoic acid tert-butyl ester was utilised with allene 
gas and Rink amide resin in the 3-component cascade and 
was thereafter acylated with benzoyl chloride to give 29 
(Scheme 5). In order to ascertain whether the cascade had 
been successful, the product was cleaved from the resin at 
this stage. Pleasingly, the mild conditions for resin cleavage 
(20% TFA in dichloromethane at room temperature for 20 
min) were also sufficient to cleave the t-butyl ester, 
resulting in carboxylic acid 30 in 74% yield and 97% 
purity.  
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N
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22
minormajor
27
26 syn
anti
Scheme 4
Although this provided a novel combinatorial route to 
carboxylic acids, our desire to carry out further resin-bound 
manipulations of these acids for diversity screening, in the 
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synthesis of pharmacologically interesting molecules, 
required a protocol whereby the esters were hydrolysed 
without cleaving from the resin. 
Although attempts to cleave the ester using zinc bromide in 
DCM proved unsatisfactory we were able to solve the 
problem of hydrolysis by using potassium 
trimethylsilanolate to hydrolyse the methyl ester.21,22 The 
cascade incorporating methyl 4-iodobenzoate proceeds 
very cleanly (Table 1, entry 8) affording resin-bound 
methyl ester 31 which was stirred overnight at room 
temperature with 4 equivalents of potassium 
trimethylsilanolate in dichloromethane (Scheme 6).  
 
Scheme 6: Reagents and conditions: a) TMSOK, DCM; b) AcOH/THF 
(1:2); c) 20% TFA/ DCM 
 
The resin-bound acid was liberated on work-up using 
mildly acidic conditions (acetic acid and tetrahydrofuran 
(1:2 v/v)) to prevent cleavage from the resin. Subsequent 
resin-cleavage confirmed that the methyl ester had been 
hydrolysed in 57% yield with purity exceeding 99%. 
3. Conclusion 
A practical method for the synthesis of diverse libraries of 
pharmacologically interesting small molecules is described. 
This method utilizes a “catch and release” approach to 
resin-bound palladium-catalysed three-component cascade 
reactions to give products in high yield and with excellent 
purity.  
In ongoing work by the authors, this resin-mediated 
reaction has been used to develop potent, novel anti-cancer 
agents. This work will be outlined in more detail in the near 
future. I
O
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Scheme 5
4. Experimental 
4.1 General 
Melting points were obtained on a Reichert hot-stage 
apparatus and are uncorrected. Microanalyses were 
performed using a Carlo Erba MOD 1106 instrument. 
Electron ionisation (EI+), fast atom bombardment (FAB+) 
and accurate molecular weight mass spectra were recorded 
on a V.G.-AutoSpec instrument operating at 70eV. 
Accurate molecular weights were determined using 
perfluorokerosine as an internal standard. Electrospray 
(ES+) mass spectra were recorded on a Micro Mass LCT 
time of flight “KA111” instrument or a Micro Mass Lynx 
NT instrument. Chemical ionisation (CI+), EI+ and 
accurate mass measurements were also performed by the 
EPSRC National Service, Swansea on a Quattro 
instrument. Infra-red spectra were recorded on a Perkins-
Elmer Spectrum One FT-IR spectrometer using a diamond 
solid-phase transmission accessory unless otherwise 
specified. HPLC analyses were recorded at 254 nm on a 
Beckman 163 variable wavelength detector using a Luna 
5μ (250 x 4.6 mm) phenyl-hexyl column unless otherwise 
stated. 1H NMR spectra were recorded at 500MHz on a 
Bruker DRX500 instrument or at 300MHz on a Bruker 
DPX300 instrument or at 250MHz on a Bruker AC250 
instrument. 13C NMR spectra were recorded at 75MHz on a 
Bruker DPX300 instrument. Spectra were determined in 
CDCl3 unless otherwise stated. Chemical shifts are given in 
parts per million (δ) downfield from tetramethylsilane (δ 
0.00). Coupling constants are given in Hertz (Hz). 1H NMR 
spectra are referenced to tetramethylsilane or residual 
protonated solvent. The following abbreviations are used: s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
br = broad, dd = double doublet, dt = double triplet, td = 
triple doublet, ddd = double double doublet. 
Dichloromethane (DCM) was distilled from calcium 
hydride. All other commercially available reagents were 
used as received and where appropriate anhydrous quality 
material was purchased. The term ether refers to diethyl 
ether. All compounds are named according to the IUPAC 
system and were obtained using the ACD/i-Lab web 
service.  
N
O
CO2Me
N
H
O
CO2H
31 30, 57% yield, >99% purity
a) to c)
4.2 General procedure: solid-phase “catch and 
release” 3-component catalytic cascade. 
Step A.  Removal of the F-moc protecting group 
20% v/v Piperidine in DMF was added to Rink Amide 
MBHA Resin (loading 0.73 mmol/g). The solution was 
agitated at room temperature for 1 h, then filtered and the 
resin washed with DMF (3x) and DCM (3x). The resin was 
dried in vacuo at room temperature over 16 h and used 
directly in Step B. 
 
Step B.  3-Component catalytic cascade   
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A Schlenk tube was charged with the resin from Step A, the 
aryl iodide (1.1 mol eq), potassium carbonate (2.0 mol eq), 
tri-2-furylphosphine (10 mol %), tris (dibenzylidene 
acetone) dipalladium (0) (2.5 mol %) and DMF (10 ml) 
followed, after two freeze, pump, thaw cycles, by allene 
gas (1 atm, 25 °C). The mixture was allowed to warm to 
room temperature and then heated at 80-100 °C with gentle 
stirring for 16 to 24 h. The mixture was then allowed to 
cool, vented, filtered and the resin washed with DCM (1x), 
water (2x), methanol (3x) and DCM (3x). The resin was 
dried in vacuo at room temperature over 16 h and used 
directly in Step C. 
 
Step C.  Acylation of the cascade product 
The acylating agent (2.0 mol eq) in anhydrous DCM (2 ml) 
was added dropwise over 2 min to a stirred solution of the 
resin from Step B, triethylamine (3.0 mol eq) and 
anhydrous DCM (10 ml) under nitrogen at 0 °C. The 
reaction mixture was allowed to warm to room temperature 
and was agitated for 16 to 24 h then filtered and the resin 
washed with DCM (1x), water (1x), methanol (2x) and 
DCM (3x). The resin was dried in vacuo at room 
temperature over 16 h and used directly in Step D. 
 
Step D. Cleavage from the resin 
The resin from Step C was slurried in 20% v/v 
trifluoroacetic acid (TFA) in DCM. The mixture was 
allowed to stand at room temperature for 20 min then 
filtered and the resin washed with DCM (2x). The 
combined filtrates were concentrated in vacuo to yield the 
product which was immediately analysed for purity by 
HPLC and if necessary further purified by flash 
chromatography and/or crystallisation. 
 
4.2.1 N-[2-(3-Nitro-phenyl)-allyl]-benzamide (8) 
Prepared by the general procedure using: 
Step A: Rink Amide MBHA Resin (0.68 g, 0.50 mmol) 
agitated in 20% v/v piperidine in dimethylformamide (10 
ml) for 1 h to give deprotected Rink Amide MBHA resin. 
Step B: The product from step A (0.50 mmol), 1-iodo-3-
nitrobenzene (137 mg, 1.1 mol eq), potassium carbonate 
(138 mg, 2.0 mol eq), tri-2-furylphosphine (12 mg, 10 mol 
%), tris (dibenzylideneacetone) dipalladium (0) (12 mg, 2.5 
mol %) and allene gas (1 atm, 25 °C) in 
dimethylformamide (10 ml). The Schlenk tube was heated 
at 80 °C for 24 h to give 6. 
Step C: Benzoyl chloride (0.116 ml, 2.0 mol eq) in 
dichloromethane (2 ml) was added dropwise to a gently 
stirred solution of 6 (0.50 mmol) and triethylamine (0.199 
ml, 3.0 mol eq) in dichloromethane (10 ml) at 0 °C. The 
mixture was agitated at room temperature for 24 h to give 
7. 
Step D: Resin 7 (0.50 mmol) was slurried in 20% v/v 
trifluoroacetic acid in dichloromethane (10 ml) and allowed 
to stand for 20 min to give the product (purity 97% by 
HPLC). Crystallisation from ethyl acetate / hexane gave 
colourless plates (134 mg, 95% overall yield from Step A), 
m.p. 111-112 °C. 
Found: C, 68.00; H, 5.25; N, 9.80; C16H14N2O3 requires: C, 
68.10; H, 5.00; N, 9.90%. 
δH (300 MHz): 8.35 (s, 1H, ArH), 8.16 (dd, 1H, J 8.2 Hz, 
4J 1.4 Hz, ArH), 7.80 (d, 1H, J 7.8 Hz, ArH), 7.71 (d, 2H, J 
7.5 Hz, ArH), 7.56-7.51 (m, 2H, ArH), 7.42 (t, 2H, J 7.7 
Hz, ArH), 6.37 (br s, 1H, NH), 5.66 (s, 1H, C=CH), 5.49 (s, 
1H, C=CH), 4.60 (d, 2H, J 5.7 Hz, NCH2). 
δC (75 MHz): 168.4 (C=O), 148.5, 142.3, 140.0, 133.5, 
132.1, 132.1, 129.7, 128.8, 126.9, 122.9, 121.1, 116.8, 43.5 
(C-N). 
m/z (ES+, %): 283 (M+H, 100). 
IR (vmax/cm-1): 1643 (C=O), 1629 (C=C), 1520 + 1350 
(NO2). 
HPLC: 97 % purity; eluted with 1:1 v/v MeCN-H2O at 0.7 
ml/min. 
 
4.2.2 N-(2-Napthalen-1-yl allyl)-benzamide (9)  
Prepared using the same method as for compound 8 but 
using 1-iodonapthalene in step B (purity 96% by HPLC). 
Further purification by flash chromatography eluting with 
3:1 v/v ether-hexane (RF 0.40) gave a pale yellow oil (134 
mg, 64% overall yield from Step A). 
Found: C, 83.10; H, 6.10; N, 4.90; C20H17NO requires: C, 
83.50; H, 5.96; N, 4.90%. 
δH (300 MHz): 8.15-8.09 (m, 1H, ArH), 7.87-7.77 (m, 2H, 
ArH), 7.72-7.67 (m, 2H, ArH), 7.49-7.31 (m, 7H, ArH), 
6.58 (t, 1H, J 4.6 Hz, NH), 5.60 (d, 1H, 2J 1.5 Hz, C=CH), 
5.24 (d, 1H, 2J 1.4 Hz, C=CH), 4.43 (d, 2H, J 4.7 Hz, 
NCH2). 
δC (75 MHz): 168.0 (C=O), 145.0, 138.9, 134.8, 134.1, 
132.0, 131.9, 129.0, 128.8, 128.4, 127.4, 126.8, 126.4, 
126.0, 125.9, 125.7, 116.4, 46.4 (C-N). 
m/z (ES+, %): 310 (M+Na, 78), 288 (M+H, 100). 
IR (vmax/cm-1): 1651 (C=O), 1635 (C=C). 
HPLC: 96 % purity; eluted with 4:1 v/v MeCN-H2O at 0.4 
ml/min. 
 
4.2.3 N-[2-(3,4-Dichloro-phenyl)-allyl]-benzamide (10) 
Prepared using the same method as for compound 8 but 
using 1,2-dichloro-4-iodobenzene in Step B (purity 96% by 
HPLC). Further purification by crystallisation from 
dichloromethane / hexane gave colourless prisms (122 mg, 
55% overall yield from Step A), m.p. 105-106 °C. 
Found: C, 62.40; H, 4.20; N, 4.40; C16H13Cl2NO requires: 
C, 62.70; H, 4.28; N, 4.60%. 
δH (300 MHz): 7.72 (dd, 2H, J 6.9 Hz, 4J 1.8 Hz, ArH), 
7.56 (d, 1H, 4J 2.0 Hz, ArH), 7.49 (d, 1H, J 7.3 Hz, ArH), 
7.42-7.39 (m, 3H, ArH), 7.31-7.26 (m, 1H, ArH), 6.37 (br 
s, 1H, NH), 5.52 (s, 1H, C=CH), 5.36 (s, 1H, C=CH), 4.49 
(d, 2H, J 5.3 Hz, NCH2). 
δC (75 MHz): 168.2 (C=O), 142.7, 138.7, 134.3, 133.2, 
132.5, 132.3, 131.0, 129.1, 128.5, 127.3, 125.8, 116.0, 43.8 
(C-N). 
m/z (ES+, %): 306 (35Cl2, M+H, 100). 
IR (vmax/cm-1): 1643 (C=O), 1629 (C=C). 
HPLC: 96 % purity; eluted with 4:1 v/v MeCN-H2O at 0.5 
ml/min. 
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4.2.4 N-[2-(6-Chloro-pyridin-3-yl)-allyl]-benzamide (11)  
Prepared using the same method as for compound 8 but 
using 2-chloro-5-iodopyridine in Step B (purity 99% by 
HPLC), colourless needles (136 mg, 68% overall yield 
from Step A), m.p. 88-89 °C. 
Found: C, 65.80; H, 4.95; N, 10.30; Cl, 12.80; 
C15H13ClN2O requires: C, 66.10; H, 4.80; N, 10.40; Cl, 
13.00%. 
δH (300 MHz): 8.50 (d, 1H, 4J 2.4 Hz, ArH), 7.79-7.71 (m, 
3H, ArH), 7.54-7.40 (m, 3H, ArH), 7.31 (d, 1H, J 8.1 Hz, 
ArH), 6.27 (br s, 1H, NH), 5.57 (s, 1H, C=CH), 5.43 (s, 
1H, C=CH), 4.54 (d, 2H, J 5.8 Hz, NCH2). 
δC (75 MHz): 167.4 (C=O), 151.0, 147.4, 140.7, 136.3, 
133.9, 133.0, 131.8, 128.7, 126.9, 124.0, 116.2, 43.2 (C-N).  
m/z (ES+, %): 273 (M+H, 100). 
IR (vmax/cm-1): 1643 (C=O), 1629 (C=C). 
HPLC: 99 % purity; eluted with 7:3 v/v MeCN-H2O at 0.5 
ml/min. 
 
4.2.5 N-[2-(3-Trifluoromethyl-phenyl)-allyl]-benzamide 
(12)   
Prepared using the same method as for compound 8 but 
using 3-iodobenzotrifluoride in Step B (purity 98% by 
HPLC). Trituration with ether gave a colourless amorphous 
solid (118 mg, 76% overall yield from Step A), m.p. 124-
125 °C. 
Found: C, 73.50; H, 6.05; N, 4.40; C19H19NO3 requires: C, 
73.80; H, 6.05; N, 4.50%. 
δH (300 MHz): 8.03 (d, 2H, J 8.3 Hz, ArH), 7.70 (d, 2H, J 
7.4 Hz, ArH), 7.55 (d, 2H, J 8.3 Hz, ArH), 7.49 (t, 1H, J 7.5 
Hz, ArH), 7.41 (t, 2H, J 7.5 Hz, ArH), 6.20 (s, 1H, NH), 
5.61 (s, 1H, C=CH), 5.42 (s, 1H, C=CH), 4.57 (d, 2H, J 5.6 
Hz, NCH2), 4.37 (q, 2H, J 7.1 Hz, OCH2), 1.39 (t, 3H, J 7.1 
Hz, CH3). 
δC (75 MHz): 167.4 (C=O), 166.3 (C=O), 143.6, 142.6, 
134.2, 131.6, 130.0, 129.9, 128.6, 126.9, 126.0, 116.0, 61.0 
(C-O), 43.5 (C-N), 14.3 (CH3). 
m/z (ES+, %): 310 (M+H, 100). 
IR (vmax/cm-1): 1723 (C=O), 1646 (C=O), 1632 (C=C). 
HPLC: 98 % purity; eluted with 7:3 v/v MeCN-H2O at 0.6 
ml/min. 
 
4.2.8 Methyl-4-{1-[benzoylamino)methyl]vinyl} 
benzoate (15) 
Prepared using the same method as for compound 8 but 
using methyl-4-iodobenzoate in Step B (purity >99% by 
HPLC). Trituration with ether gave a colourless amorphous 
solid (120 mg, 82% overall yield from Step A), m.p. 136-
137 °C. 
Found: C, 71.80; H, 5.85; N, 4.50; C18H17NO3 0.25H2O 
requires: C, 72.00; H, 5.80; N, 4.70%. 
δH (300 MHz): 8.02 (d, 2H, J 8.4 Hz, ArH), 7.70 (d, 2H, J 
7.4 Hz, ArH), 7.55 (d, 2H, J 8.4 Hz, ArH), 7.49 (t, 1H, J 7.4 
Hz, ArH), 7.41 (t, 2H, J 7.5 Hz, ArH), 6.20 (br s, 1H, NH), 
5.62 (s, 1H, C=CH), 5.43 (s, 1H, C=CH), 4.57 (d, 2H, J 5.4 
Hz, NCH2), 3.91 (s, 3H, Me). 
δC (75 MHz): 167.8 (C=O), 166.4 (C=O), 143.9, 143.2, 
134.6, 132.1, 130.3, 130.1, 129.1, 127.3, 126.5, 116.4, 52.6 
(C-N), 43.9 (C-O). 
m/z (ES+, %): 295 (M+H, 100).  
HRMS: Found [M+H] 295.1199, [C18H17NO3+H] requires 
295.1203. 
IR (vmax/cm-1): 1720 (C=O), 1643 (C=O), 1626 (C=C). 
HPLC: 99.5 % purity; eluted with 3:1 v/v MeCN-H2O at 
0.6 ml/min. 
 
4.2.9 Methyl-4-(1-{[(biphenyl-4-ylcarbonyl)amino] 
methyl}vinyl) benzoate (16)  
Prepared using the same method as for compound 8 but 
using methyl-4-iodobenzoate in Step B and 4-biphenyl 
carbonyl chloride in Step C (purity 94% by HPLC). 
Trituration with ether gave colourless needles (131 mg, 
71% overall yield from Step A), m.p. 198-199 °C. 
Found: C, 76.80; H, 5.60; N, 3.70; C24H21NO3 0.25 H2O 
requires: C, 76.70; H, 5.80; N, 3.70%. 
δH (300 MHz): 8.03 (dd, 2H, J 8.3 Hz, 4J 1.7 Hz, ArH), 
7.70 (d, 2H, J 8.3 Hz, ArH), 7.64-7.55 (m, 6H, ArH), 7.46 
(t, 2H, J 8.3 Hz, ArH), 7.41 (d, 1H, J 8.0 Hz, ArH), 6.24 (br 
s, 1H, NH), 5.64 (s, 1H, C=CH), 5.45 (s, 1H, C=CH), 4.59 
(d, 2H, J 5.6 Hz, NCH2), 3.91 (s, 3H, Me). 
δC (75 MHz): 167.1 (C=O), 166.4 (C=O), 144.5, 143.6, 
142.8, 139.9, 133.1, 129.9, 129.7, 128.9, 128.0, 127.4, 
127.3, 127.2, 126.1, 116.1 (C=C), 52.26 (C-N), 43.5 (C-O). 
m/z (EI+, %): 371 (M+H, 100).  
HRMS: Found [M+H] 371.1519, [C24H21NO3+H] requires 
371.1516. 
IR (vmax/cm-1): 1715 (C=O), 1639 (C=O), 1607 (C=C). 
HPLC: 94 % purity; eluted with 3:1 v/v MeCN-H2O at 0.3 
ml/min. 
 
4.2.10 N-[2-Napthalen-1-yl-allyl]-3-phenyl-urea (17)            
Prepared using the same method as for compound 8 but 
using 1-iodonapthalene in Step B and phenyl isocyanate in 
Step C (purity 92% by HPLC). Further purification by flash 
chromatography eluting with ether (RF 0.42) gave 
colourless needles (136 mg, 90% overall yield from Step 
A), m.p. 98-99 °C. 
Found: C, 79.40; H, 5.80; N, 9.30; C20H18N2O requires: C, 
79.40; H, 6.00; N, 9.30%. 
δH (300 MHz): 7.99 (dd, 1H, J 6.4 Hz, 4J 3.1 Hz, ArH), 
7.88-7.69 (m, 2H, ArH), 7.51-7.38 (m, 3H, ArH), 7.29-7.19 
(m, 3H, ArH), 7.10 (t, 1H, J 7.4 Hz, ArH), 6.98 (d, 2H, J 
7.4 Hz, ArH), 5.56 (d, 1H, 2J 1.0 Hz, C=CH), 5.22 (s, 1H, 
C=CH), 4.22 (s, 2H, NCH2). 
δC (75 MHz): 157.9 (C=O), 145.0, 138.4, 137.2, 134.1, 
131.8, 130.0, 128.8, 128.4, 126.8, 126.4, 126.0, 125.7, 
125.6, 123.6, 116.7, 47.0 (C-N). 
m/z (ES+, %): 303 (M+H, 100). 
IR (vmax/cm-1): 1683 (C=O), 1621 (C=C). 
HPLC: 92 % purity; eluted with 4:1 v/v MeCN-H2O at 0.8 
ml/min. 
 
4.2.11 1-Cyclohexyl-3-[2-(3-nitro-phenyl)-allyl]-urea 
(18)               
 Tetrahedron  9
Prepared using the same method as for compound 8 but 
using 3-iodonitrobenzene in Step B and cyclohexyl 
isocyanate in Step C (purity 90% by HPLC). Further 
purification by crystallisation from dichloromethane / 
hexane gave colourless needles (97 mg, 64% overall yield 
from Step A), m.p. 95-96 °C. 
Found: C, 63.10; H, 7.00; N, 13.60; C16H21N3O3 requires: 
C, 63.30; H, 6.98; N, 13.80%. 
δH (300 MHz): 8.29 (t, 1H, 4J 2.0 Hz, ArH), 8.15 (dt, 1H, J 
8.0 Hz, 4J 2.0 Hz, ArH), 7.78 (dt, 1H, J 7.9 Hz, 4J 1.9 Hz, 
ArH), 7.52 (t, 1H, J 8.0 Hz, ArH), 5.57 (s, 1H, C=CH), 
5.41 (s, 1H, C=CH), 4.36 (br s, 1H, NH), 4.30 (d, 2H, J 5.4 
Hz, NCH2), 4.27 (br s, 1H, NH), 3.51 (m, 1H, CyH), 1.93-
1.89 (m, 2H, CyH), 1.70-1.50 (m, 4H, CyH), 1.41-1.27 (m, 
2H, CyH), 1.19-1.06 (m, 2H, CyH). 
δC (75 MHz): 157.0 (C=O), 148.4, 143.8, 140.5, 132.2, 
129.5, 122.7, 121.2, 115.8, 49.4 (C-N), 44.0 (C-N), 33.8 
(C-C) 25.5 (C-C), 24.9 (C-C). 
m/z (ES+, %): 305 (M+H, 100). 
IR (vmax/cm-1): 1640 (C=O), 1621 (C=C) 1532 + 1343 
(NO2). 
HPLC: 90 % purity; eluted with 4:1 v/v MeCN-H2O at 0.8 
ml/min. 
 
4.2.12 4-Methyl-N-({[2-(3-nitrophenyl)prop-2-en-1-
yl]amino}carbonyl)benzene sulfonamide (19)            
Prepared using the same method as for compound 8 but 
using 3-iodonitrobenzene in Step B and p-toluenesulfonyl 
isocyanate in Step C (purity 99% by HPLC), colourless 
plates (128 mg, 68% overall yield from Step A), m.p. 136-
137 °C. 
Found: C, 54.50; H, 4.80; N, 11.0; S, 8.50; C17H17N3O5S 
requires: C, 54.40; H, 4.56; N, 11.2; S, 8.50%. 
δH (300 MHz): 8.20 (t, 1H, 4J 1.9 Hz, ArH), 8.19 (dd, 1H, J 
8.1 Hz, 4J 1.7 Hz, ArH), 7.98 (br s, 1H, NH), 7.69 (d, 1H, J 
7.8 Hz, ArH), 7.59 (d, 2H, J 8.3 Hz, ArH), 7.48 (t, 1H, J 8.0 
Hz, ArH), 7.19 (d, 2H, J 8.1 Hz, ArH), 6.80 (t, 1H, J 5.4 
Hz, NH), 5.57 (s, 1H, C=CH), 5.35 (s, 1H, C=CH), 4.34 (d, 
2H, J 5.6 Hz, NCH2), 2.41 (s, 3H, CH3). 
δC (75 MHz): 158.0 (C=O), 151.6, 145.5, 142.4, 140.2, 
136.6, 132.4, 130.3, 129.9, 127.1, 123.2, 121.5, 117.2, 44.0 
(C-N), 22.0 (CH3).  
m/z (ES+, %): 398 (M+Na, 91), 376.3 (M+H, 100). 
IR (vmax/cm-1): 1695 (C=O), 1631 (C=C) 1549 + 1344 
(NO2). 
HPLC: 99 % purity; eluted with 7:3 v/v MeCN-H2O: 70/30 
at 0.5 ml/min. 
 
4.3.1 N-[(2Z)-3-Cyclohexyl-2-(3-nitrophenyl)prop-2-en-
1-yl] benzamide (25) 
Prepared using the same method as for compound 8 but 
with the following change to Step B: 
 
Step B: To the resin from Step A was added 3-
iodonitrobenzene (137 mg, 1.1 mol eq), cyclohexylallene 
(122 mg, 2.0 mol eq), tris (dibenzylideneacetone) 
dipalladium (12 mg, 2.5 mol %), tri-2-furylphosphine (12 
mg, 10 mol %) and potassium carbonate (138 mg, 2.0 mol 
eq). The mixture was agitated under nitrogen for 24 h, 
filtered and the resin washed with methanol (10 ml), water 
(10 ml), methanol (2 x 10 ml), dichloromethane (3 x 10 ml) 
and dried in vacuo at room temperature over 16 h. 
 
The combined filtrates following cleavage in Step D were 
concentrated in vacuo to give an 11:1 mixture of Z and E 
stereoisomers (overall purity 97% by HPLC). 
Crystallisation from acetonitrile yielded the major Z-isomer 
25 as colourless prisms (120 mg, 66% overall yield from 
Step A), m.p. 97-98 °C. Attempted isolation of the minor 
isomer by flash chromatography proved unsuccessful. 
Found: C, 72.30; H, 6.60; N, 7.70; C22H24N2O3 requires: C, 
72.50; H, 6.64; N, 7.70%. 
δH (300 MHz): 8.28 (t, 1H, 4J 1.9 Hz, ArH), 8.08 (dd, 1H, J 
8.1 Hz, 4J 1.8 Hz, ArH), 7.74 (dd, 1H, J 7.9 Hz, 4J 1.8 Hz, 
ArH), 7.63 (dd, 2H, J 7.6 Hz, 4J 2.0 Hz, ArH), 7.50-7.45 
(m, 2H, ArH), 7.40-7.36 (m, 2H, ArH), 5.95 (d, 1H, J 9.5 
Hz, C=CH), 5.89 (s, 1H, NH), 4.62 (d, 2H, J 5.2 Hz, 
NCH2), 2.59-2.53 (m, 1H, CyH), 1.80-1.70 (m, 5H, CyH), 
1.42-1.33 (m, 2H, CyH), 1.28-1.21 (m, 3H, CyH). 
δC (75 MHz): 168.9 (C=O), 148.9, 142.6, 142.1, 134.6, 
132.6, 132.0, 129.9, 129.0, 127.2, 122.4, 121.5, 38.8 (C-N), 
38.3 (C-C), 33.7 (C-C), 26.2 (C-C), 26.0 (C-C).  
m/z (ES+, %): 365 (M+H, 100). 
IR (vmax/cm-1): 1643 (C=O), 1633 (C=C). 
HPLC: 97 % purity; eluted with 7:3 v/v MeCN-H2O at 0.5 
ml/min. 
 
4.4.1 4-[1-(Benzoylamino-methyl)-vinyl] benzoic acid 
(30)              
 
a. Via hydrolysis of resin-bound tert-butyl ester 
Prepared using the same method as for compound 8 but 
using 4-iodobenzoic acid tert-butyl ester in Step B (purity 
97% by HPLC), colourless amorphous solid (103 mg, 74% 
overall yield from Step A), m.p. 194-195 °C. 
Found: C, 70.60; H, 5.30; N, 4.70; C17H15NO3 0.5 H2O 
requires: C, 70.30; H, 5.38; N, 4.80%. 
δH (DMSO-d6, 500 MHz): 8.86 (t, 1H, J5.6 Hz, NH), 7.94 
(d, 2H, J 8.3 Hz, ArH), 7.86 (d, 2H, J 7.3 Hz, ArH), 7.67 
(d, 2H, J 8.3 Hz, ArH), 7.53 (t, 1H, J 7.3 Hz, ArH), 7.47 (t, 
2H, J 7.4 Hz, ArH), 5.64 (s, 1H, C=CH), 5.34 (s, 1H, 
C=CH), 4.37 (d, 2H, J 5.6 Hz, NCH2). 
δC (DMSO-d6, 75 MHz): 167.4 (C=O), 166.6 (C=O), 
144.1, 143.2, 134.6, 131.6, 130.3, 129.8, 128.7, 127.6, 
126.3, 114.6, 42.5 (C-N). 
m/z (ES+, %): 282.3 (M+H, 100). 
HRMS: Found [M+H] 281.1046, [C17H15NO3+H] requires 
281.1046. 
IR (vmax/cm-1): 3300-2300 (O-H), 1673 (C=O), 1642 
(C=O), 1607 (C=C). 
HPLC: 98 % purity; eluted with 7:3 v/v MeCN-H2O at 0.3 
ml/min. 
 
b. Via hydrolysis of resin-bound methyl ester  
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Resin-bound methyl ester 31 (0.50 mmol) was prepared by 
following Steps A, B and C of the procedure for compound 
15. 
Silanolate conversion of methyl ester 31 
Resin-bound methyl ester 31 (0.50 mmol) was added to an 
agitated slurry of potassium trimethyl silanolate (257 mg, 
4.0 mol eq) in dry dichloromethane (10 ml) at room 
temperature under nitrogen. The reaction mixture was 
agitated for 16 h and the resin filtered and washed with 
methanol (10 ml), water (10 ml) and methanol (10 ml). The 
resin was then acidified with 1:2 v/v acetic acid in 
tetrahydrofuran, filtered and washed with methanol (10 
ml), water (10 ml), methanol (10 ml) and dichloromethane 
(2 x 10 ml). The resin was dried in vacuo at room 
temperature over 16 h and used directly in the next step. 
Cleavage from the resin to give acid 30 
The resin from the hydrolysis step (0.50 mmol) was 
slurried in 20% v/v trifluoroacetic acid in dichloromethane 
(10 ml) and allowed to stand for 20 min to give 30 (purity 
>99% by HPLC) as a colourless amorphous solid (80 mg, 
57% overall yield from Step A). 
HPLC: >99 % purity; eluted with 7:3 MeCN-H2O at 0.4 
ml/min. 
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